Mirati Therapeutics reported $-176445000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Astellas Pharma 4503:JP Y 31679M 42195M
AstraZeneca AZN:LN 258259.83M 36783.7M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Eisai 4523:JP Y 9722M 30501M
Exelixis EXEL:US $ 88.51M 3.28M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Novartis NOVN:VX SF 4129M 217M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Spectrum Pharmaceuticals SPPI:US $ -29.03M 13.65M
Takeda 4502:JP Y 155473M 209520M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M